Quality of Earnings in Healthcare: Why Standard QoE Falls Short

Introduction

Quality of earnings analysis is the cornerstone of financial diligence in any M&A transaction, but in healthcare, the standard QoE framework (which focuses on revenue sustainability, expense normalization, and EBITDA bridge adjustments) misses critical sector-specific issues. Healthcare revenue is not simply "revenue"; it is a complex construct that flows through payer contracts, coding and billing processes, contractual allowance estimates, and regulatory programs (Medicare, Medicaid, 340B) that each introduce layers of risk and adjustment not present in other industries.

In a standard QoE for a technology or industrial company, the revenue line is relatively straightforward: the company invoices customers, customers pay, and revenue is recognized. The QoE analyst focuses on revenue recognition timing, customer concentration, and one-time items.

In healthcare, the revenue process is fundamentally different. The provider delivers a service, codes it using CPT/HCPCS codes, submits a claim to the payer (or multiple payers), the payer adjudicates the claim against the contracted reimbursement rate (which differs by payer, plan, and service), the payer pays a portion (often different from the billed amount), and the patient may owe a copay or deductible. The difference between what the provider bills and what it collects (the "contractual allowance") can be 30-70% of billed charges.

Contractual Allowance

The difference between a healthcare provider's billed charges (the gross amount submitted to the payer) and the actual reimbursement received under the provider's contract with that payer. If a provider bills $1,000 for a procedure but the payer contract specifies a reimbursement rate of $400, the contractual allowance is $600 (60%). Contractual allowances are estimated in the financial statements because the provider does not know the exact reimbursement for each claim at the time revenue is recorded. Inaccurate contractual allowance estimates can materially misstate net revenue, and this estimate is one of the highest-risk areas in healthcare QoE.

Payer Mix Decomposition

Healthcare QoE must decompose net patient revenue by payer category (commercial, Medicare, Medicaid, self-pay, workers' compensation) and ideally by individual payer within each category. This decomposition reveals:

Contractual Allowance Accuracy

Contractual allowance estimates are inherently subjective and represent one of the largest estimation risks in healthcare financial statements. A provider that over-estimates its contractual allowances (expects to collect less than it actually does) will show a positive "true-up" when actual collections exceed estimates. A provider that under-estimates allowances (expects to collect more than it actually does) will show a negative true-up, effectively overstating revenue.

Healthcare QoE must analyze the contractual allowance true-up history: is the provider consistently over- or under-estimating? Consistent positive true-ups suggest conservative revenue recognition (good). Consistent negative true-ups or large swings suggest estimation issues that may mask declining reimbursement (bad).

Coding Compliance Risk

The accuracy of medical coding directly affects revenue. Upcoding (assigning a higher-complexity code than the service warrants) generates higher reimbursement but creates fraud and abuse risk. Undercoding (assigning lower-complexity codes) leaves revenue on the table. Healthcare QoE should include a coding compliance review, typically performed by a specialized healthcare coding consultant, that analyzes a sample of medical records against the codes submitted for billing.

340B Program Diligence

340B Drug Pricing Program

A federal program that requires drug manufacturers to sell outpatient drugs at discounted prices (typically 25-50% below average wholesale price) to eligible healthcare organizations, primarily safety-net hospitals, federally qualified health centers, and certain other covered entities. The covered entity purchases the drug at the 340B price but can bill commercial and government payers at the standard reimbursement rate, generating a "spread" that can be substantial. 340B revenue can represent 5-15% of total net revenue for eligible entities, and the program's rules and eligibility requirements are complex and frequently litigated.

For targets that participate in the 340B program, QoE must quantify the 340B spread (the difference between the 340B acquisition cost and the reimbursement received), verify eligibility (is the entity properly enrolled, are the covered outpatient facilities registered, are contract pharmacy arrangements compliant), and assess the risk of 340B program changes that could reduce or eliminate the spread.

Provider Compensation Normalization

In physician practice management transactions, physician compensation is often the largest expense line and the most subject to manipulation. Pre-acquisition, physician-owners may pay themselves above or below market rates, and the QoE must normalize compensation to fair market value to determine the sustainable EBITDA of the practice post-acquisition.

The next article covers the Corporate Practice of Medicine doctrine and the MSO-PC structures that healthcare transactions use to navigate it.